Diversified holds up to 5 names from all sectors above $500M, with no more than one per industry at any time. Selection follows the model's volatility score.
Strategy
Equal capital goes into every recommendation. Recommendations are published a few hours before the open and placed as market orders, so buys and sells fill at the opening price. Positions are held for 6 to 21 days. Every position carries a 20% stop-loss: if the price touches it during the day, the position is sold there, at 80% of its entry price. Reported returns are measured from those opening prices and include every stop-loss exit.
Baron letter cites 27% ARR growth and raised FY guidance
Baron's Q3 2026 investor letter disclosed that Netskope contributed 0.93% to returns at the Baron SMID Cap ETF, citing 27% year-over-year ARR growth, revenue growth of 29%, an 11-point operating margin improvement, and a raised full-year guidance. Institutional endorsement plus fundamental momentum narrative can attract momentum and fund flows in the near term.
NTSK traded up about 5.18% intraday to $22.55, holding above its weekly (~$22.01) and quarterly (~$18.49) moving averages after consolidating in the $21-22 range. Technical strength and volume expansion raise the probability of a retest of the late-October high near $26.52, though weakening MACD momentum is a caveat.
Wells Fargo and Morgan Stanley raised their price targets to $50 and $48 respectively, with consensus at Moderate Buy (10 Buy, 1 Sell). Multiple PT hikes following earnings can extend positive sentiment and attract incremental buyers.
Shares fall 5.3% on light volume, no clear catalyst
VIA dropped 5.3% to $42.27 on Wednesday on volume ~78% below average, with no specific catalyst identified. The pullback reflects profit-taking after the post-earnings rally and lingering concerns over unprofitability and converting pipeline into sustainable profits, a mild near-term negative.
Citizens raises PT to $55 from $37, Market Outperform
Citizens sharply lifted its price target to $55 (from $37) while maintaining Market Outperform, citing the Q3 beat, 31% growth acceleration, and record $574M run-rate revenue. The large PT increase reinforces bullish analyst sentiment and could support near-term buying interest.
RBC lifts NTSK target to $23, maintains Outperform
Royal Bank of Canada raised its price target on Netskope from $20 to $23 while keeping an "outperform" rating, implying roughly 8% upside from the prior close. Sell-side target revisions of this kind typically draw incremental buyers and reinforce the "Moderate Buy" consensus (average target ~$19.82), supporting near-term sentiment.
Via reported Q3 2026 revenue of $143.5M (+31% YoY) versus ~$138M consensus, adjusted net loss per share rounding to breakeven, and FY2026 revenue guidance of $556.7M-$558.4M above the $551.7M consensus. The beat-and-raise drove a ~14% single-day rally, signaling strong short-term positive momentum.
Company guides to first profitable quarter in Q4 2026
Management indicated Q4 2026 should be the first quarter with positive adjusted EBITDA and adjusted EPS, with Q4 adjusted EBITDA guided to $0.0-$1.5M. This profitability inflection is a key near-term narrative driver that could sustain investor optimism into the next report.
CEO David J. Wilson bought 32,631 shares (~$551,349) at an average of $16.90 on Nov. 5, not under a pre-arranged plan, per a Form 4 filing. Open-market CEO buying shortly after a strong earnings beat signals insider confidence and can support positive short-term sentiment.
On Nov 6, Northland Securities raised its FY2026 EPS estimate to $3.05 from $2.68 (above the $2.96 consensus) and FY2027 to $3.26 from $3.11, citing improved earnings growth expectations post-Q3. Upward estimate revisions typically support positive near-term momentum.
Mixed analyst actions; JPMorgan cuts price target to $110
JPMorgan lowered its ALNT price target to $110 from $120 while maintaining a Neutral rating (Nov 6), a modest negative signal. This was partly offset by upgrades to Strong-Buy from Wall Street Zen and Zacks Research, leaving a Moderate Buy consensus and a $82.33 average target.
Q3 2026 record revenue, margins and orders beat estimates
Allient reported Q3 2026 revenue of $164.4M (+18% YoY) and adjusted EPS of $1.07, beating the $0.74 consensus by $0.33. Record orders of $218.1M (+64% YoY, 1.33x book-to-bill) and record backlog of $351.5M (+52% YoY) provide strong forward visibility, a clear positive catalyst for near-term sentiment.
Netskope sets FQ3 2027 earnings for December 2, 2026
Netskope will report fiscal third quarter 2027 results (quarter ended October 31, 2026) after the close on December 2, 2026, with a call at 5:00 pm ET. The confirmed date focuses investor attention on the print; company guidance is for a Q3 loss of $0.04 to $0.03 per share, so positioning and any pre-earnings estimate revisions are the near-term drivers.
CMCO reported Q2 FY27 net sales of $539.3M (+107% Y/Y) and Adjusted EPS of $0.61, beating consensus of ~$518.6M and $0.38 respectively, with Adjusted EBITDA margin up 520 bps to 20.6%. Management raised FY27 guidance for net sales, Adjusted EBITDA, and Adjusted EPS, and the stock jumped double digits on the release, a clear positive near-term sentiment driver.
Q3 2026 results beat; full-year revenue and cash guidance raised
OmniAb reported Q3 2026 revenue of $4.0M vs $2.2M a year ago and a narrower net loss of $0.12/share, then raised FY2026 revenue guidance to $35-39M (from $32-36M) and lifted year-end cash outlook to $53-57M. The beat-and-raise reinforces the durability of the licensing/royalty model and is a positive near-term signal, though the report is now nearly two weeks old and largely digested.
The Board declared a $0.07 per share dividend payable on or about November 16, 2026 to holders of record as of November 6, 2026. The imminent payment date is a minor, routine event with limited price impact but confirms continued capital returns.
Harbour BioMed announced China's NMPA approved batoclimab for anti-AChR antibody-positive generalized myasthenia gravis, the fourth drug approved from OmniAb's platform. This creates a potential future royalty stream, though management noted it is too early to determine pricing or royalty impact, limiting immediate financial effect.
xPloration platform broadened to all customers; OmniTides introduced
OmniAb expanded commercial access to its xPloration single B-cell screening platform to all customers starting October 2026 and introduced the OmniTides peptide discovery offering at its Investor & Analyst Day. Management expects xPloration revenue of $2-3M in 2026, doubling in 2027 and again in 2028, supporting a longer-term growth narrative but with limited immediate revenue impact.
Major shareholder Lightspeed Venture Partners sold 10,621 shares at an average price of $14.90 (~$158k) in a transaction dated September 11, 2026, disclosed via SEC filing. The size is small relative to the float and the disclosure is dated, so price impact is likely limited, but continued insider selling by a large holder is a mild overhang.
Eli Lilly ion-channel collaboration worth up to $370M milestones
OmniAb signed a global collaboration and license agreement with Eli Lilly for a new ion channel program, receiving an upfront payment plus eligibility for up to $370M in milestones and tiered royalties. Service revenue from the Lilly collaboration is expected to begin contributing in Q4 2026, providing a tangible near-term revenue catalyst and validating the platform.